MediGene AG engages in the clinical research and development of novel drugs against cancer and autoimmune diseases with focus on personalized immunotherapies. It operates through the following business segments: Marketed Products and Drug Candidates. The Marketed Products segment consists of the drugs Eligard and Veregen. The Drug Candidates segment involves in product development and the creation of new product candidates. The company was founded by Ernst Ludwig Winnacker and Horst Domdey in June, 1994 and is headquartered in Martinsried, Germany.